血清肿瘤标志物在卵巢恶性肿瘤诊断中的ROC曲线分析
ROC Curve Analysis of Serum Tumor Markers in the Diagnosis of Ovarian Malignant Tumors
DOI: 10.12677/ACM.2022.12121663, PDF,    科研立项经费支持
作者: 马沈倩, 任志帅, 刘 畅, 杨舒文:郑州大学人民医院妇产科,河南 郑州;郭玉琪*:郑州大学人民医院妇产科,河南 郑州;河南省人民医院妇产科,河南 郑州
关键词: 卵巢癌血管内皮生长因子人附睾蛋白4糖类抗原125糖类抗原724Ovarian Cancer Vascular Endothelial Growth Factor Human Epididymis Protein 4 Carbohydrate Antigen 125 Carbohydrate Antigen 724
摘要: 目的:探讨血清血管内皮生长因子(VEGF)、人附睾蛋白4 (HE4)、糖类抗原125 (CA125)、糖类抗原724 (CA724)在卵巢恶性肿瘤中的诊断价值。方法:回顾性分析郑州大学人民医院2020至2021年的卵巢恶性肿瘤患者106例,按术后常规病理结果将其分为上皮性肿瘤组97例、生殖细胞肿瘤组5例、性索间质肿瘤组4例。测定各组患者血清VEGF、HE4、CA125、CA724水平,绘制受试者工作特征(ROC)曲线并计算曲线下面积(AUC),计算各血清标志物的敏感性和特异性,比较单项及联合检测对卵巢恶性肿瘤的诊断价值。结果:ROC曲线显示在上皮性卵巢癌与非上皮性卵巢癌的鉴别诊断及FIGO分期的鉴别诊断中,血清VEGF、HE4、CA125、CA724的4项指标的联合检测的AUC明显高于单项检测、2项及3项指标的联合检测,且敏感度和特异性更高,差异有统计学意义(P < 0.05)。结论:血清VEGF、HE4、CA125及CA724的水平与卵巢恶性肿瘤的发生发展密切相关,可作为卵巢恶性肿瘤鉴别诊断的检测指标,且联合检测诊断效能更高,对卵巢恶性肿瘤的早期诊断具有重要意义。
Abstract: Objective: To investigate the diagnostic value of serum vascular endothelial growth factor (VEGF), human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125), and carbohydrate antigen 724 (CA724) in ovarian malignant tumors. Methods: 106 patients with ovarian malignant tumors in the People’s Hospital of Zhengzhou University from 2020 to 2021 were retrospectively analyzed. According to the postoperative routine pathological results, they were divided into 97 cases of epi-thelial tumors, 5 cases of germ cell tumors, and 4 cases of sex cord-stromal tumors. The levels of VEGF, HE4, CA125, and CA724 in the serum of patients in each group were measured, the ROC curve of subjects was drawn, the area under the curve (AUC) was calculated, and the sensitivity and speci-ficity of serum markers were calculated, and the diagnostic value of single and combined detection for ovarian malignant tumors was compared. Results: The ROC curve showed that in the differential diagnosis of epithelial ovarian cancer and non-epithelial ovarian cancer and the differential diagno-sis of FIGO staging, the AUC of the combined detection of serum VEGF, HE4, CA125, CA724 was sig-nificantly higher than that of the single detection, the combined detection of two and three indica-tors, and the sensitivity and specificity were higher, with a statistically significant difference (P < 0.05). Conclusion: The levels of VEGF, HE4, CA125, and CA724 in serum are closely related to the occurrence and development of ovarian malignant tumors, which can be used as the detection indi-cators for differential diagnosis of ovarian malignant tumors, and the combined detection has high-er diagnostic efficacy, which is of great significance for the early diagnosis of ovarian malignant tu-mors.
文章引用:马沈倩, 任志帅, 刘畅, 杨舒文, 郭玉琪. 血清肿瘤标志物在卵巢恶性肿瘤诊断中的ROC曲线分析[J]. 临床医学进展, 2022, 12(12): 11534-11541. https://doi.org/10.12677/ACM.2022.12121663

参考文献

[1] Sung, H., Ferlay, J., Siegel, R., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Siegel, R., Miller, K. and Jemal, A. (2020) Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7-30. [Google Scholar] [CrossRef] [PubMed]
[3] Orr, B. and Edwards, R. (2018) Diagnosis and Treatment of Ovarian Can-cer. Hematology/Oncology Clinics of North America, 32, 943-964. [Google Scholar] [CrossRef] [PubMed]
[4] Matulonis, U., Sood, A., Fallowfield, L., et al. (2016) Ovarian Cancer. Nature Reviews Disease Primers, 2, Article No. 16061. [Google Scholar] [CrossRef] [PubMed]
[5] Gershenson, D., Bodurka, D., Lu, K., et al. (2015) Impact of Age and Primary Disease Site on Outcome in Women with Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. Journal of Clinical Oncology: Official Journal of the American So-ciety of Clinical Oncology, 33, 2675-2682. [Google Scholar] [CrossRef
[6] Torre, L., Trabert, B., DeSantis, C., et al. (2018) Ovarian Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 284-296. [Google Scholar] [CrossRef] [PubMed]
[7] Jemal, A., Tiwari, R., Murray, T., et al. (2004) Cancer Statistics, 2004. CA: A Cancer Journal for Clinicians, 54, 8-29. [Google Scholar] [CrossRef] [PubMed]
[8] du Bois, A., Quinn, M., Thigpen, T., et al. (2005) 2004 Consensus Statements on the Management of Ovarian Cancer: Final Document of the 3rd International Gynecologic Cancer Inter-group Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Annals of Oncology: Official Journal of the Euro-pean Society for Medical Oncology, 16, viii7-viii12. [Google Scholar] [CrossRef] [PubMed]
[9] Perren, T., Swart, A., Pfisterer, J., et al. (2011) A Phase 3 Trial of Bevacizumab in Ovarian Cancer. The New England Journal of Medicine, 365, 2484-2496. [Google Scholar] [CrossRef
[10] Banerjee, S., Moore, K., Colombo, N., et al. (2020) 811MO Maintenance Olaparib for Patients (pts) with Newly Diagnosed, Advanced Ovarian Cancer (OC) and a BRCA Mutation (BRCAm): 5-Year (y) Follow-Up (f/u) from SOLO1. Annals of Oncology, 31, S613. [Google Scholar] [CrossRef
[11] Wang, L. (2019) Prognostic Effect of Programmed Death-Ligand 1 (PD-L1) in Ovarian Cancer: A Systematic Review, Meta-Analysis and Bioinformatics Study. Journal of Ovarian Research, 12, 37. [Google Scholar] [CrossRef] [PubMed]
[12] Kohan-Ivani, K., Gabler, F., Selman, A., et al. (2016) Role of Di-hydrotestosterone (DHT) on TGF-β1 Signaling Pathway in Epithelial Ovarian Cancer Cells. Journal of Cancer Research and Clinical Oncology, 142, 47-58. [Google Scholar] [CrossRef] [PubMed]
[13] Zheng, L., Qu, J. and He, F. (2016) The Diagnosis and Patholog-ical Value of Combined Detection of HE4 and CA125 for Patients with Ovarian Cancer. Open Medicine (Warsaw, Po-land), 11, 125-132. [Google Scholar] [CrossRef] [PubMed]
[14] Melincovici, C., Boca, A., Uman, S., et al. (2018) Vascular Endothe-lial Growth Factor (VEGF)—Key Factor in Normal and Pathological Angiogenesis. Romanian Journal of Morphology and Embryology, 59, 455-467.
[15] Stiekema, A., Boldingh, Q., Korse, C., et al. (2015) Serum Human Epididymal Protein 4 (HE4) as Biomarker for the Differentiation between Epithelial Ovarian Cancer and Ovarian Metastases of Gas-trointestinal Origin. Gynecologic Oncology, 136, 562-566. [Google Scholar] [CrossRef] [PubMed]
[16] Guadagni, F., Roselli, M., Cosimelli, M., et al. (1995) CA 72-4 Serum Marker—A New Tool in the Management of Carcinoma Patients. Cancer Investigation, 13, 227-238. [Google Scholar] [CrossRef] [PubMed]
[17] Yang, Z., Zhao, B. and Li, L. (2016) The Significance of the Change Pattern of Serum CA125 Level for Judging Prognosis and Diagnosing Recurrences of Epithelial Ovarian Cancer. Journal of Ovarian Research, 9, 57. [Google Scholar] [CrossRef] [PubMed]
[18] Al-Musalhi, K., Al-Kindi, M., Ramadhan, F., et al. (2015) Valid-ity of Cancer Antigen-125 (CA-125) and Risk of Malignancy Index (RMI) in the Diagnosis of Ovarian Cancer. Oman Medical Journal, 30, 428-434. [Google Scholar] [CrossRef] [PubMed]
[19] Li, K., Pei, Y., Wu, Y., et al. (2020) Performance of Matrix-Assisted La-ser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF-MS) in Diagnosis of Ovarian Cancer: A Systematic Review and Meta-Analysis. Journal of Ovarian Research, 13, 6. [Google Scholar] [CrossRef] [PubMed]
[20] Dochez, V., Caillon, H., Vaucel, E., et al. (2019) Biomarkers and Algorithms for Diagnosis of Ovarian Cancer: CA125, HE4, RMI and ROMA, a Review. Journal of Ovarian Research, 12, 28. [Google Scholar] [CrossRef] [PubMed]
[21] Granato, T., Midulla, C., Longo, F., et al. (2012) Role of HE4, CA72.4, and CA125 in Monitoring Ovarian Cancer. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, 33, 1335-1339. [Google Scholar] [CrossRef] [PubMed]